| Similar Articles |
|---|
 |
Chemistry World
May 26, 2015
Phillip Broadwith |
Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt.   |
Chemistry World
September 2, 2013
Emma Stoye |
Endo Health to buy Boca Pharmacal for $225m US speciality healthcare company Endo Health Solutions has agreed to buy Boca Pharmacal for $225 million in a bid to expand its generics business. |
The Motley Fool
September 29, 2010
Brian Orelli |
A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals. |
Chemistry World
March 25, 2015
Phillip Broadwith |
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. |
The Motley Fool
August 1, 2007
Brian Lawler |
Calling Out Endo Endo Pharmaceuticals gets taken to task by an activist investor. An investment group owning 5.6% of outstanding shares is concerned with how management plans to use $700 million available to them in cash and investments. |
The Motley Fool
February 25, 2008
Brian Lawler |
The Yin and Yang of Endo Endo Pharmaceuticals' fiscal 2007 report offered positive year-end financial results and a little bit of balance-sheet sourness. |
The Motley Fool
April 30, 2007
Brian Lawler |
Nothing Wrong With Endo Endo Pharmaceuticals releases first-quarter financial results. Investors, take note. |
The Motley Fool
April 12, 2011
Arundhati Parmar |
Endo Acquires Pelvic Care Firm American Medical Systems The company that began life in the pharmaceutical sector is venturing forth into devices in its quest to become more of a diversified health-care company. |
The Motley Fool
January 19, 2007
Brian Lawler |
The Best Drug Stock for 2007: Endo Pharmaceuticals This drug-maker just might be a great investment at the current price. |
The Motley Fool
January 30, 2008
Brian Lawler |
The Endo a CEO Shares of Endo Pharmaceutical rise after its CEO, Peter Lankau, resigns. |
The Motley Fool
August 3, 2007
Brian Lawler |
Endo Adjusting to Bigger Hopes The pharma announces its second-quarter financial results. As worries recede about near-term generic competition for lead drug Lidoderm, expectations for Endo have grown. |
The Motley Fool
October 23, 2006
Brian Lawler |
Not the End for Endo An FDA decision won't hurt the maker of Lidoderm. Investors, take note. |
The Motley Fool
April 30, 2008
Brian Lawler |
The Start of a New Endo The drugmaker marks its first quarter under new management. |
The Motley Fool
February 26, 2007
Brian Lawler |
Endo Brings in the Dough Why buy this pharmaceutical? Investors, let me count the ways. |
The Motley Fool
December 30, 2010
Brian Orelli |
That's What You Call Product Differentiation? Endo Pharma misses the mark with its treatment for low testosterone, which the Food and Drug Administration approved yesterday. |
The Motley Fool
January 10, 2007
Brian Lawler |
Endo's Plan to Bring In the Dough Despite little movement in the value of their shares, 2006 was an eventful year for investors in drug developer Endo Pharmaceuticals. |
Chemistry World
June 7, 2013
Phillip Broadwith |
Job cuts at three US pharma companies Endo will shed 15% of its global workforce by mid 2014; Impax is cutting 110 manufacturing and sales positions (around 12% of its workforce); and Zogenix is laying off 55 of its 148 staff (37%). |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders. |
The Motley Fool
November 6, 2007
Brian Lawler |
The Two Sides of Endo It has been a mixed third quarter for Endo Pharmaceuticals. On the financial side of things the company performed well; on the research and development side, things are not as good. |
The Motley Fool
March 29, 2005
Charly Travers |
A Biotech Value Play Sometimes you have to invest against the grain. Take a look at Canadian drug company QLT. |
The Motley Fool
January 22, 2007
Brian Lawler |
The Feds Eye Endo Endo Pharmaceuticals' sales practices for Lidoderm prompt government scrutiny. Investors don't seem too concerned. |
The Motley Fool
October 31, 2011
Tim Beyers |
Auxilium Pharmaceuticals Shares Plunged: What You Need to Know Shares of Auxilium Pharmaceuticals fell more than 13% in early trading after the company revealed lower demand for procedures relating to the hand disorder known as Dupuytren's contracture. |
The Motley Fool
January 10, 2011
Travis Hoium |
Auxilium Pharmaceuticals Shares Popped: What You Need to Know Auxilium Pharmaceuticals shares are 15% higher today after the company released preliminary fourth-quarter results. |
The Motley Fool
November 29, 2007
Brian Lawler |
QLT Goes on the Block QLT announced yesterday that it's in the preliminary stages of exploring a sale. |
The Motley Fool
August 31, 2004
Charly Travers |
Hidden Value With QLT The market might overlook the drug maker's promising programs. Over the next six months, biotech investors should keep an eye on this one. |
The Motley Fool
October 26, 2006
Brian Lawler |
QLT Quickly Losing Traction The biotech company gets hammered by a competitor's superior product. There was one bright spot in the quarter for QLT, though. Investors, take note. |
BusinessWeek
October 29, 2009
Arlene Weintraub |
Testosterone Is Sure Looking Virile Despite legal setbacks and FDA delays, youth-crazed boomers are making testosterone a billion-dollar industry. |
The Motley Fool
April 1, 2008
Brian Lawler |
The Endo a Patent? Endo sues to protect a lead drug from generic competition. |
The Motley Fool
April 30, 2007
Brian Orelli |
No Pain for Endo's Investors Endo Pharmaceuticals had an impressive first quarter thanks to a new product and continued sales growth of its older brands. Investors, take note. |
The Motley Fool
February 26, 2007
Brian Lawler |
Is QLT the Comeback Kid? The Canadian drugmaker updates investors on its outlook for 2007. |
